Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase IIIII randomized, double-blind trial to evaluate acetyl-L-carnitine ALCAR in adults living with amyotrophic lateral sclerosis ALS. The main goal is to assess how two doses of ALCAR 1.5gday and 3gday affect the progression of functional disability measured by the ALSFRS-R scale. Secondary aims include examining ALCARs impact on respiratory function, quality of life, cognitive performance, survival, and disease biomarkers related to the drugs mechanisms. Participants will be randomly assigned to one of three groups ALCAR 1.5gday, ALCAR 3gday, or placebo, all alongside riluzole treatment. The study lasts 48 weeks, during which participants take the assigned medication three times daily. Follow-up visits occur at 4, 12, 24, 36, and 48 weeks to monitor health status, collect blood samples for biomarker testing, and perform various clinical assessments. Throughout the study, participants undergo evaluations including vital signs, neurological exams, respiratory tests, cognitive and quality of life assessments, and compliance checks. Researchers measure changes in functional disability, respiratory capacity, cognitive function, quality of life, biomarker levels, and survival rates. Safety is also monitored by recording adverse events. Participants will be followed until death after the trial period.